LY03015
/ Luye Group
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
January 23, 2025
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
(clinicaltrials.gov)
- P1/2 | N=120 | Recruiting | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Movement Disorders
December 12, 2024
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
(clinicaltrials.gov)
- P1/2 | N=120 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1/2 trial • Movement Disorders
December 12, 2024
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
(clinicaltrials.gov)
- P1 | N=16 | Completed | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Completed
Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders
December 12, 2024
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: Luye Pharma Group Ltd. | Recruiting ➔ Completed
Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders
June 25, 2024
Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders
January 29, 2024
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=104 | Completed | Sponsor: Luye Pharma Group Ltd. | Recruiting ➔ Completed
Trial completion • Genetic Disorders • Huntington's Disease • Movement Disorders
January 22, 2024
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Luye Pharma Group Ltd.
New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders
April 26, 2023
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=104 | Recruiting | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2023 ➔ Oct 2023 | Trial primary completion date: Jan 2023 ➔ Oct 2023
Enrollment open • Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders
1 to 8
Of
8
Go to page
1